Curia New York Files for DEA Permission on Controlled Drug Imports
Published Date: 8/11/2025
Notice
Summary
Curia New York Inc wants to become an official importer of certain controlled substances. This means they’ll be allowed to bring in specific drugs that are carefully regulated. If approved, it could impact businesses and researchers who rely on these substances, with timing and money details to watch for in the official info.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 0 costs, 1 mixed.
Importer Registration Application Filed
Curia New York Inc has applied to be registered as an importer of certain controlled substances. If their registration is approved, businesses and researchers that rely on those regulated drugs could be affected. The Federal Register notice points readers to supplementary information for which drugs, timing, and any cost details.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-22843, Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2027
The DEA is setting limits on how much of certain controlled drugs and chemicals can be made in 2027. This affects drug makers and anyone involved in producing or handling these substances. They’re asking for public comments by December 10, 2026, before finalizing the amounts, which helps keep drug supply safe and balanced.
2026-22842, Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sale) Pursuant to 21 U.S.C. 826(h)
The DEA is boosting the 2026 production limits for four important medicines: d,l-amphetamine, d-amphetamine (for sale), hydromorphone, and methylphenidate (for sale). This change helps fix shortages and keeps medicines flowing smoothly. The new quotas take effect right away on November 10, 2026, so manufacturers can ramp up production without delay.
Previous / Next Documents
Previous: 2025-15155, Importer of Controlled Substances Application: Galephar Pharmaceutical Research Inc
Galephar Pharmaceutical Research Inc wants to become an official importer of certain controlled substances. This means they’ll be allowed to bring in specific drugs that need special handling. If approved, this could affect companies and regulators keeping an eye on drug imports, with no immediate cost changes announced.
Next: 2025-15157, Bulk Manufacturer of Controlled Substances Application: Cambrex Charles City
Cambrex Charles City wants to get official approval to make large amounts of certain controlled substances. This affects anyone involved in drug manufacturing and regulation, with no immediate cost or deadline changes announced. It’s a key step for them to legally produce these important chemicals.